B-Cell Malignancies—Expert Guidance on BTK Inhibitors for Today’s Clinic

In this clinic-focused program review the latest data on current and emerging strategies leveraging BTK inhibitors to manage MCL CLL and other B-cell malignancies with an on-demand Webcast capturing expert discussion from the 2019 meeting in Chicago. Then download the meeting slidesets to help guide your treatment decisions.

Share

Program Content

Activities

BTKi Combination Therapy
Looking Toward the Future: BTKi-Based Combination Therapy
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2019

Expires: June 03, 2020

BTK Inhibitor Treatments
Optimizing the Use of BTK Inhibitors in B-Cell Malignancies
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2019

Expires: June 03, 2020

Managing BTK Inhibitor AEs
Managing Adverse Events Associated With BTK Inhibitors
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2019

Expires: June 03, 2020

BTK Targeting Rationale
Rationale for Targeted Therapy Toward BTK in B-Cell Malignancies
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: June 05, 2019

Expires: June 03, 2020

No activities added yet

Faculty

cover img faculity

John C. Byrd, MD

D. Warren Brown Chair of Leukemia Research
Professor of Medicine,
Medicinal Chemistry and Veterinary Biosciences
Director, Division of Hematology
Department of Medicine
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute
Columbus, Ohio

cover img faculity

Ian Flinn, MD, PhD

Chief Scientific Officer
OneOncology
Nashville, Tennessee

cover img faculity

Andrew D. Zelenetz, MD, PhD

Associate Professor, Department of Medicine
Cornell University Medical College
Chief, Lymphoma Service
Memorial Sloan-Kettering Cancer Center
New York, New York

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

AstraZeneca